Novation News
Derma Sciences Signs Innovative Technology Agreement With Novation for MEDIHONEY(TM) Wound & Burn Dressings
"This is our third key group purchasing organization (GPO) agreement for MEDIHONEY, and we continue to be encouraged that Novation and other organizations seek to provide access to this important new technology to their members," said
The MEDIHONEY line of dressings, containing Active Leptospermum Honey, is used for managing a wide variety of wounds and burns. In July, the FDA gave its initial clearance of MEDIHONEY, and the product was launched last fall. Two additional clearances for line extensions have been granted since that time. Sales have increased rapidly, and over 20 clinical abstracts on the use of the product have been accepted at various professional conferences so far in 2008.
Novation defines new medical technology as a new device or product that offers an incremental patient care or safety benefit over devices or products currently available and that are used to diagnose or treat a patient by a clinician. In addition, a new device or product may be the first of its kind in the market or an improvement over existing technology within the same product class or category.
About Novation(R)
Founded in 1998, Novation is the leading health care contracting services company for more than 2,500 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 13,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand — the licensor of the patented honey- based technology — and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The
Contact: Derma Sciences, Inc. Allen & Caron Inc Edward J. Quilty Rudy Barrio (US Investors) Chairman and CEO r.barrio@allencaron.com equilty@dermasciences.com (609) 514-4744 Brian Kennedy (media) brian@allencaron.com (212) 691-8087
SOURCE Derma Sciences, Inc.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
